💊FDA Orders GLP-1 Warnings for Eating Disorders, Vision Loss, and Blindness

Your GLP-1 patients may need new warning conversations

The FDA just ordered GLP-1 drugs to carry new warnings covering eating disorders, vision loss, and blindness. That's three distinct risks, and the label change lands on every product in the class. If you're building anything on top of GLP-1 data, this hits you. Health apps, medication reminders, pharmacy integrations, and EHR alerts all pull from label text. Stale copy is a compliance problem waiting to happen, so audit where your product quotes these labels. The agency's language covers eating disorders, vision loss, and blindness as separate warnings. The catch is that the source material gives no effective date or rollout schedule, so treat timing as unconfirmed until the FDA publishes the final text. Worth watching: how manufacturers word the blindness language, since that wording will get copied everywhere.